TY - JOUR
T1 - Prognosis of polymerase epsilon (POLE) mutation in high-grade endometrioid endometrial cancer
T2 - Systematic review and meta-analysis
AU - Casanova, Joao
AU - Duarte, Gonçalo Silva
AU - da Costa, Ana Gomes
AU - Catarino, Ana
AU - Nave, Mónica
AU - Antunes, Telma
AU - Serra, Sofia Silvério
AU - Dias, Sara Simões
AU - Abu-Rustum, Nadeem
AU - Lima, Jorge
N1 - Funding Information:
This work in the context of the “Women's Health and Maternal Fetal Research Group” was partially co-financed by Hospital da Luz Lisboa under the initiative “Luz Investigação”. Dr. Abu-Rustum was supported in part by a National Cancer Institute/National Institutes of Health Cancer Center Support Grant ( P30 CA008748 ). The funding sources were not involved in study design; collection, analysis and interpretation of data; the writing of the report; or the decision to submit the paper for publication.
Funding Information:
This work in the context of the “Women's Health and Maternal Fetal Research Group” was partially co-financed by Hospital da Luz Lisboa under the initiative “Luz Investigação”. Dr. Abu-Rustum was supported in part by a National Cancer Institute/National Institutes of Health Cancer Center Support Grant (P30 CA008748). The funding sources were not involved in study design; collection, analysis and interpretation of data; the writing of the report; or the decision to submit the paper for publication.
Publisher Copyright:
© 2024 The Authors
PY - 2024/3
Y1 - 2024/3
N2 - Background: POLE mutated endometrial carcinomas may represent a subspecific type of tumors harboring a more favorable prognosis. Grade 3 (G3 or high-grade) endometrioid endometrial carcinomas remain a clinical dilemma, with some tumors behaving as the low-grade counterparts and others presenting a more aggressive behavior. Objectives: To determine the association between POLE mutational status and the overall-survival (OS) and progression-free-survival (PFS) of patients with G3 endometrioid endometrial cancer (EC). We also aimed to determine the prevalence of POLE mutations in G3 endometrioid EC. Methods: We conducted a systematic review in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (PROSPERO No: CRD4202340008). We searched the following electronic databases: PubMed/Medline, EMBASE, Cochrane Library, Scopus, and Web of Science. For time-to-event data, the effect of POLE mutation in G3 EC was described using hazard ratios (HRs) and corresponding 95% confidence intervals (CIs). Individual patient data for each study was investigated if available from the study authors. If individual patient data were not available, information regarding time-to-event outcomes was extracted using an appropriate methodology. OS and PFS were analyzed using both one-stage and two-stage approaches, the Kaplan-Meier method, and Cox-proportional hazards models. Results: This systematic review and meta-analysis included 19 studies with 3092 patients who had high-grade endometrioid EC. Patients with POLE mutations had lower risks of death (HR = 0.36, 95% CI 0.26 to 0.50, I2 = 0%, 10 trials) and disease progression (HR = 0.31, 95% CI 0.17 to 0.57, I2 = 33%, 10 trials). The pooled prevalence of POLE mutation was 11% (95% CI 9 to 13, I2 = 68%, 18 studies). Conclusion: POLE mutations in high-grade endometrioid EC are associated with a more favorable prognosis with increased OS and PFS.
AB - Background: POLE mutated endometrial carcinomas may represent a subspecific type of tumors harboring a more favorable prognosis. Grade 3 (G3 or high-grade) endometrioid endometrial carcinomas remain a clinical dilemma, with some tumors behaving as the low-grade counterparts and others presenting a more aggressive behavior. Objectives: To determine the association between POLE mutational status and the overall-survival (OS) and progression-free-survival (PFS) of patients with G3 endometrioid endometrial cancer (EC). We also aimed to determine the prevalence of POLE mutations in G3 endometrioid EC. Methods: We conducted a systematic review in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (PROSPERO No: CRD4202340008). We searched the following electronic databases: PubMed/Medline, EMBASE, Cochrane Library, Scopus, and Web of Science. For time-to-event data, the effect of POLE mutation in G3 EC was described using hazard ratios (HRs) and corresponding 95% confidence intervals (CIs). Individual patient data for each study was investigated if available from the study authors. If individual patient data were not available, information regarding time-to-event outcomes was extracted using an appropriate methodology. OS and PFS were analyzed using both one-stage and two-stage approaches, the Kaplan-Meier method, and Cox-proportional hazards models. Results: This systematic review and meta-analysis included 19 studies with 3092 patients who had high-grade endometrioid EC. Patients with POLE mutations had lower risks of death (HR = 0.36, 95% CI 0.26 to 0.50, I2 = 0%, 10 trials) and disease progression (HR = 0.31, 95% CI 0.17 to 0.57, I2 = 33%, 10 trials). The pooled prevalence of POLE mutation was 11% (95% CI 9 to 13, I2 = 68%, 18 studies). Conclusion: POLE mutations in high-grade endometrioid EC are associated with a more favorable prognosis with increased OS and PFS.
KW - Endometrial cancer
KW - Endometrioid
KW - High-grade
KW - Meta-analysis
KW - POLE
KW - Prognosis
KW - Systematic review
UR - http://www.scopus.com/inward/record.url?scp=85183539203&partnerID=8YFLogxK
U2 - 10.1016/j.ygyno.2024.01.018
DO - 10.1016/j.ygyno.2024.01.018
M3 - Review article
C2 - 38262245
AN - SCOPUS:85183539203
SN - 0090-8258
VL - 182
SP - 99
EP - 107
JO - Gynecologic Oncology
JF - Gynecologic Oncology
ER -
